Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

@article{Palandri2008ChronicML,
  title={Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.},
  author={Francesca Palandri and Fausto Castagnetti and Nicoletta Testoni and Simona Luatti and G. Marzocchi and Simona Bassi and Massimo Breccia and Giuliana Alimena and Ester Pungolino and Giovanna Rege-Cambrin and Riccardo Varaldo and Maurizio Miglino and Giorgina Specchia and Eliana Zuffa and Felicetto Ferrara and Monica Bocchia and Giuseppe Saglio and Fabrizio Pane and Daniele Alberti and Giovanni Martinelli and Michele Baccarani and Gianantonio Rosti},
  journal={Haematologica},
  year={2008},
  volume={93 12},
  pages={1792-6}
}
BACKGROUND Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients. DESIGN AND METHODS We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…